ALEXION PHARMACEUTICALS INC

Alexion Pharmaceuticals Inc. specializes in the manufacturing of specialized pharmaceutical preparations, with a demonstrated focus on rare disease therapeutics and biologics production. Their technical expertise centers on aseptic processing, lyophilization, and GMP-compliant manufacturing of high-potency injectable drugs, particularly for hematologic and metabolic conditions. The company’s key differentiator lies in its ability to consistently deliver complex, low-volume specialty pharmaceuticals under strict regulatory oversight, ensuring product stability, purity, and patient safety. Their work involves end-to-end pharmaceutical development lifecycle support, from formulation scaling to commercial-scale production, with deep familiarity with FDA and VA-specific compliance requirements. The Department of Veterans Affairs is their primary federal partner, with a sustained pattern of procurement for targeted biologic therapeutics, including the drug Strensiq, used in the treatment of hyperphosphatasia. Their engagements with VA reflect a long-term, mission-critical supply relationship, likely tied to specialty pharmacy networks serving veterans with rare metabolic disorders. Work includes direct product delivery, option exercises under blanket purchase agreements, and fulfillment under Federal Supply Schedule contracts, indicating a trusted vendor status within VA’s pharmaceutical distribution infrastructure. Alexion operates primarily under NAICS 325412, which encompasses the manufacturing of pharmaceutical preparations, particularly those requiring advanced biotechnological processes. Their market positioning is in the niche segment of orphan drug manufacturing, where precision, regulatory rigor, and supply chain reliability are paramount. They serve a specialized segment of the biopharmaceutical market focused on ultra-rare indications requiring tailored production protocols. As a 2L entity based in Boston, MA, Alexion Pharmaceuticals Inc. is structured as a mid-tier manufacturer with no active government certifications on record. Their geographic presence is centered in a major biopharma hub, enabling access to skilled labor, research institutions, and logistics networks critical to maintaining a compliant, responsive supply chain for federal healthcare programs.